Suppr超能文献

2D/3D 直接作用抗病毒方案治疗 HCV 诱导的 Child-Pugh A 肝硬化的安全性:一项汇总分析。

Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis.

机构信息

The Texas Liver Institute/University of Texas Health, San Antonio, TX, USA.

Division of Gastroenterology, Hepatology & Nutrition, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.

出版信息

J Hepatol. 2017 Oct;67(4):700-707. doi: 10.1016/j.jhep.2017.06.011. Epub 2017 Jun 21.

Abstract

BACKGROUND & AIMS: Chronic hepatitis C virus (HCV)-infected patients with cirrhosis are a high-priority population for treatment. To help inform the benefit-risk profile of the all-oral direct-acting antiviral (DAA) combination regimen of ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir (OBV/PTV/r±DSV) in patients with Child-Pugh A cirrhosis, we undertook a comprehensive review of AbbVie-sponsored clinical trials enrolling patients with Child-Pugh A cirrhosis.

METHODS

Twelve phase II or III clinical trials of the 2-DAA regimen of OBV/PTV/r±ribavirin (RBV) or the 3-DAA regimen of OBV/PTV/r+DSV±RBV that included patients with Child-Pugh A cirrhosis were reviewed; patients who completed treatment by November 16, 2015 were included in a pooled, post hoc safety assessment. The number and percentage of patients with treatment-emergent adverse events (TEAEs), serious TEAEs, and TEAEs consistent with hepatic decompensation were reported.

RESULTS

In 1,066 patients with Child-Pugh A cirrhosis, rates of serious TEAEs and TEAEs leading to study drug discontinuation were 5.3% (95% confidence interval [CI]: 4.1-6.8) and 2.2% (95% CI: 1.4-3.2), respectively. Thirteen patients (1.2%; 95% CI: 0.7-2.1) had a TEAE that was consistent with hepatic decompensation. The most frequent TEAEs consistent with hepatic decompensation were ascites (n=8), esophageal variceal hemorrhage (n=4), and hepatic encephalopathy (n=2).

CONCLUSIONS

This pooled analysis in 1,066 HCV-infected patients with Child-Pugh A cirrhosis confirms the safety of OBV/PTV/r±DSV±RBV in this population. These results support the use of OBV/PTV/r±DSV±RBV in this high-priority population. Lay summary: This pooled safety analysis in 1,066 HCV-infected patients with compensated cirrhosis, receiving treatment with ombitasvir, paritaprevir, and ritonavir with or without dasabuvir, with or without ribavirin, shows that the rate of hepatic decompensation events was similar to previously reported rates in untreated patients.

摘要

背景与目的

慢性丙型肝炎病毒(HCV)感染合并肝硬化患者是治疗的重点人群。为了更好地了解全口服直接作用抗病毒药物(DAA)联合治疗方案(奥比帕利/帕立瑞韦/利托那韦,联合或不联合达沙布韦)在伴有 Child-Pugh A 级肝硬化患者中的获益-风险特征,我们对艾伯维赞助的伴有 Child-Pugh A 级肝硬化的患者进行了全面的临床试验回顾。

方法

对 12 项 II 期或 III 期 2-DAAs 方案(奥比帕利/帕立瑞韦/利托那韦联合或不联合利巴韦林)或 3-DAAs 方案(奥比帕利/帕立瑞韦/利托那韦联合达沙布韦联合或不联合利巴韦林)的临床试验进行了回顾,这些试验纳入了伴有 Child-Pugh A 级肝硬化的患者;截止至 2015 年 11 月 16 日完成治疗的患者被纳入事后安全性评估的汇总分析。报告了治疗期间出现的不良事件(TEAEs)、严重 TEAEs 和与肝失代偿一致的 TEAEs 的患者数量和百分比。

结果

在 1066 例伴有 Child-Pugh A 级肝硬化的患者中,严重 TEAEs 和导致研究药物停药的 TEAEs 发生率分别为 5.3%(95%可信区间:4.1-6.8)和 2.2%(95%可信区间:1.4-3.2)。13 例(1.2%;95%可信区间:0.7-2.1)患者发生与肝失代偿一致的 TEAEs。最常见的与肝失代偿一致的 TEAEs 为腹水(n=8)、食管静脉曲张出血(n=4)和肝性脑病(n=2)。

结论

这项纳入 1066 例伴有 Child-Pugh A 级肝硬化的 HCV 感染患者的汇总分析证实了在该人群中使用奥比帕利/帕立瑞韦/利托那韦联合达沙布韦联合或不联合利巴韦林的安全性。这些结果支持在这一高优先级人群中使用奥比帕利/帕立瑞韦/利托那韦联合达沙布韦联合或不联合利巴韦林。

非医学专业人员摘要

本项纳入 1066 例伴有代偿性肝硬化、接受奥比帕利/帕立瑞韦/利托那韦联合或不联合达沙布韦联合或不联合利巴韦林治疗的 HCV 感染患者的安全性汇总分析显示,肝失代偿事件的发生率与未治疗患者的先前报告率相似。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验